The Calcutta High Court has clarified the standards for product-by-process patent claims in India, focusing on the necessity of expert evidence in infringement cases. The decision in West Bengal Chemicals v. GTZ provides important guidance for pharmaceutical patent litigation.
Read more about Clarifying Product-by-Process Patent Claims in India – West Bengal Chemicals v. GTZTag: Pharmaceutical patents
Boehringer secures Patent Injunction for its Diabetes Drug – Empagliflozin
The Himachal Pradesh High Court has granted Boehringer Ingelheim an interim injunction against Eris Lifesciences, preventing the manufacture and sale of Empagliflozin during the suit. The case provides insights into the judicial approach towards pharmaceutical patent disputes in India.
Read more about Boehringer secures Patent Injunction for its Diabetes Drug – EmpagliflozinCancerous Battle: Novartis and NATCO clash over Eltrombopag
The Delhi High Court Division Bench set aside an injunction against Natco Pharma in the Novartis Eltrombopag patent dispute. The judgment provides key guidance on patent validity challenges and the requirements under Section 3(d) of the Patents Act in pharmaceutical cases.
Read more about Cancerous Battle: Novartis and NATCO clash over EltrombopagProduct by Process Patent Claims are Product Claims, not Process Claims, rules the Delhi High Court
The Delhi High Court has ruled that product by process patent claims are to be treated as product claims, not process claims, for both patentability and infringement analysis. This judgment clarifies the legal position and ensures consistent standards for evaluating pharmaceutical and other complex inventions in India.
Read more about Product by Process Patent Claims are Product Claims, not Process Claims, rules the Delhi High CourtExamining the Origins of Section 3(d) in India’s Patents Act and Its Connection to EU SPCs
The article analyses Section 3(d) of India’s Patents Act and its controversial role in pharmaceutical patents post-Novartis. It examines its origins, connection to EU SPCs, and the focus on preventing evergreening by emphasising enhanced efficacy.
Read more about Examining the Origins of Section 3(d) in India’s Patents Act and Its Connection to EU SPCsRevisiting Supplementary Protection Certificates of the European Union
The article examines the structure and implications of supplementary protection certificates in the European Union. It reviews their regulatory evolution, procedural requirements, and influence on pharmaceutical market exclusivity, while also considering comparative perspectives from India.
Read more about Revisiting Supplementary Protection Certificates of the European UnionProfiting from the Patent Cliff: What Drug Manufacturers Need to Know about Secondary Patents
This post explores how drug manufacturers leverage secondary patents to manage the patent cliff and maintain exclusivity. A detailed analysis of Entresto’s patent timeline and Indian legal context is provided.
Read more about Profiting from the Patent Cliff: What Drug Manufacturers Need to Know about Secondary PatentsLatest Patent Cases in 2022 – Part 1
This post analyses recent Indian patent cases from 2022, focusing on notable court decisions such as MSN Laboratories v. Novartis Ag. It provides legal insights into patent infringement and injunctions in the pharmaceutical sector.
Read more about Latest Patent Cases in 2022 – Part 1Recap 2021- Indian Patent Case Laws
This post analyses major Indian patent case laws from 2021, with a focus on Delhi High Court decisions involving interim injunctions and pharmaceutical patents. It offers an objective summary of key judgments relevant to patent infringement and validity in India.
Read more about Recap 2021- Indian Patent Case LawsLatest Patent Cases in 2021 – Part 3
This article examines recent patent litigation before the Delhi High Court, highlighting cases involving Novartis and Sulphur Mills in 2021. It discusses key judicial findings on patent validity, scope, and interim injunctions in Indian pharmaceutical and agricultural sectors.
Read more about Latest Patent Cases in 2021 – Part 3